Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Grants and contracts	$ 8,487,966	$ 3,570,710	$ 8,790,209
Operating expenses:
Research and development	19,525,950	22,501,805	22,788,887
General and administrative	12,038,775	11,115,511	11,106,493
Total operating expenses	31,564,725	33,617,316	33,895,380
Loss from operations	(23,076,759)	(30,046,606)	(25,105,171)
Other income:
Interest and other income (expense)	83,127	(70,015)	53,659
Change in value of warrant liability	2,864,348	7,701,981	19,821,787
Total other income	2,947,475	7,631,966	19,875,446
Net loss	(20,129,284)	(22,414,640)	(5,229,725)
Net loss attributable to noncontrolling interests	2,866,407	4,180,498	1,216,055
Net loss attributable to Cleveland BioLabs, Inc.	$ (17,262,877)	$ (18,234,142)	$ (4,013,670)
Net loss available to common stockholders per share of common stock, basic and diluted	$ (0.38)	$ (0.49)	$ (0.12)
Weighted average number of shares used in calculating net loss per share, basic and diluted	45,002,823	37,388,847	32,561,743